HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

CPMC Holdings (906.HK) - ORG Can't Afford to Lose, But Baosteel Is a Step Ahead

L'Occitane (973.HK) - The Privatization Is About to Succeed

Shanghai Henlius Biotech Privatization (2696.HK) - The Offer Price Is Disappointing

Akeso Biopharma (9926.HK) - It's Not Game over Yet

China TCM (570.HK) Update - Despite Doubts, This Privatization Seems “Mandatory”

Shanghai Henlius Biotech (2696.HK) - Behind the Trading Halt and Privatization Rumor

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

Event-Driven

Shanghai Fosun Pharmaceutical (Group) / Event-Driven

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

<ul>
<li>It is said that Fosun Pharma plans to privatize Henlius. There’re doubts about how to solve the debt problem/cash flow pressure of Fosun Pharma. A third party could be involved.</li>
<li>Shareholders may not be willing to accept an Offer Price that is significantly below IPO price. It’s also possible that shareholders vote against the privatization. So, there are many uncertainties.</li>
<li>Deal talks are still ongoing. It's difficult to see clearly what's happening under the table. Valuation logic of Fosun Pharma should be more like PE/VC firms not traditional pharmaceutical company.</li>
</ul>


It is said that Fosun Pharma plans to privatize Henlius. There’re doubts about how to solve the debt problem/cash flow pressure of Fosun Pharma. A third party could be involved.
Shareholders may not be willing to accept an Offer Price that is significantly below IPO price. It’s also possible that shareholders vote against the privatization. So, there are many uncertainties.
Deal talks are still ongoing. It's difficult to see clearly what's happening under the table. Valuation logic of Fosun Pharma should be more like PE/VC firms not traditional pharmaceutical company.


Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Fosun Pharma (2196 HK/600196.CH) To Privatize Henlius (2696.HK) - Things Are Not as Good as Expected